Clinical evidence of a graft-versus-Hodgkin's-lymphoma effect after reduced-intensity allogeneic transplantation (Q45159702)

10 December 2017

Clinical evidence of a graft-versus-Hodgkin's-lymphoma effect after reduced-intensity allogeneic transplantation (English)

1 reference

10 December 2017

4

1 reference

10 December 2017

Emma C Morris

11

0 references

Charles Craddock

object named as

Charles Craddock

7

0 references

Herman Waldmann

object named as

Herman Waldmann

13

0 references

Geoff Hale

12

object named as

Geoff Hale

1 reference

10 December 2017

15

David C Linch

1 reference

10 December 2017

14

Anthony H Goldstone

1 reference

10 December 2017

1

Karl S Peggs

1 reference

10 December 2017

3

Rajesh Chopra

1 reference

10 December 2017

5

Premini Mahendra

1 reference

10 December 2017

16

Stephen Mackinnon

1 reference

10 December 2017

10

Kirsty J Thomson

1 reference

10 December 2017

8

Ruth Pettengell

1 reference

10 December 2017

Ann Hunter

2

1 reference

10 December 2017

Donald Milligan

6

1 reference

10 December 2017

Ahmet Dogan

9

1 reference

10 December 2017

language of work or name

English

0 references

publication date

1 June 2005

1 reference

10 December 2017

1 reference

10 December 2017

365

1 reference

10 December 2017

9475

1 reference

10 December 2017

1934-1941

1 reference

Autologous hematopoietic cell transplantation in Hodgkin's disease

10 December 2017

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2966659-7

7 January 2021

Aggressive conventional chemotherapy compared with high-dose chemotherapy with autologous haemopoietic stem-cell transplantation for relapsed chemosensitive Hodgkin's disease: a randomised trial

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2966659-7

7 January 2021

High-dose sequential chemotherapy and peripheral blood progenitor cell autografting in patients with refractory and/or recurrent Hodgkin lymphoma: a multicenter study of the intergruppo Italiano Linfomi showing prolonged disease free survival in pat

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2966659-7

7 January 2021

Allogeneic, syngeneic, and autologous marrow transplantation for Hodgkin's disease: the 21-year Seattle experience

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2966659-7

7 January 2021

Bone marrow transplants from HLA-identical siblings in advanced Hodgkin's disease.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2966659-7

7 January 2021

Allogeneic bone marrow transplant is not better than autologous transplant for patients with relapsed Hodgkin's disease. European Group for Blood and Bone Marrow Transplantation.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2966659-7

7 January 2021

Long-term results of blood and marrow transplantation for Hodgkin's lymphoma

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2966659-7

7 January 2021

Role of allogeneic stem cell transplantation in relapsed or refractory Hodgkin's disease

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2966659-7

7 January 2021

'GVHD': graft-versus-host disease or graft-versus-Hodgkin's disease? An old acronym with new meaning

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2966659-7

7 January 2021

Donor leukocyte infusions in relapsed Hodgkin's lymphoma following allogeneic stem cell transplantation: CD3+ cell dose, GVHD and disease response

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2966659-7

7 January 2021

Graft-versus-tumor induction with donor leukocyte infusions as primary therapy for patients with malignancies

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2966659-7

7 January 2021

Allogeneic peripheral blood stem cell transplantation following fludarabine-based conditioning in six children with advanced Hodgkin's disease

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2966659-7

7 January 2021

Pharmacokinetics of alemtuzumab used for in vivo and in vitro T-cell depletion in allogeneic transplantations: relevance for early adoptive immunotherapy and infectious complications

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2966659-7

7 January 2021

Defining opportunistic invasive fungal infections in immunocompromised patients with cancer and hematopoietic stem cell transplants: an international consensus.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2966659-7

7 January 2021

Statistical methods for the analysis and presentation of the results of bone marrow transplants. Part I: unadjusted analysis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2966659-7

7 January 2021

Statistical methods for the analysis and presentation of the results of bone marrow transplants. Part 2: Regression modeling

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2966659-7

7 January 2021

Applying Cox regression to competing risks.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2966659-7

7 January 2021

Role of Nonmyeloablative Allogeneic Stem-Cell Transplantation After Failure of Autologous Transplantation in Patients With Lymphoproliferative Malignancies

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2966659-7

7 January 2021

Fludarabine in the management of malignant lymphomas

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2966659-7

7 January 2021

Immunohistochemical analysis of CDw52 antigen expression in non-Hodgkin's lymphomas

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2966659-7

7 January 2021

Allogeneic stem cell transplantation with fludarabine-based, less intensive conditioning regimens as adoptive immunotherapy in advanced Hodgkin's disease

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2966659-7

7 January 2021

Can positron emission tomography with [(18)F]-fluorodeoxyglucose after first-line treatment distinguish Hodgkin's disease patients who need additional therapy from others in whom additional therapy would mean avoidable toxicity?

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2966659-7

7 January 2021

Prognostic value of pretransplantation positron emission tomography using fluorine 18-fluorodeoxyglucose in patients with aggressive lymphoma treated with high-dose chemotherapy and stem cell transplantation

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2966659-7

7 January 2021

10.1016/S0140-6736(05)66659-7

Identifiers

DOI

1 reference

10 December 2017

1 reference